Hypertension due to RAAS activation can be addressed at each of the steps of the system: renin inhibitors directly inhibit renin and prevent its downstream effects (e.g. aliskiren), angiotensin-converting enzyme inhibitors block the conversion of angiotensin I to II (e.g. lisinopril), angiotensin II receptor blockers block angiotensin II receptors (e.g. losartan), and aldosterone antagonists inhibit aldosterone effects (e.g. spironolactone). Here, REN is linked to hypertensive disorder.